Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3680387 | 0.74 | MEN1 (0.54) | MEN1MAPTKMT2A | |
| SCHEMBL426787 | 0.68 | EDNRA (0.35) | — | |
| SCHEMBL30736092 | 0.67 | MEN1 (0.44) | MEN1MAPTKMT2A | |
| SCHEMBL25826358 | 0.67 | MEN1 (0.44) | MEN1MAPTKMT2A | |
| SCHEMBL31360488 | 0.66 | ALDH1A1 (0.31) | MAPT | |
| SCHEMBL30736216 | 0.65 | SIRT6 (0.43) | MEN1MAPTKMT2A | |
| SCHEMBL18343470 | 0.65 | MAPK1 (0.44) | MEN1MAPTKMT2A | |
| SCHEMBL25231594 | 0.64 | MEN1 (0.44) | MEN1MAPTKMT2A | |
| SCHEMBL2644333 | 0.64 | MEN1 (0.44) | MEN1MAPTKMT2A | |
| SCHEMBL23171261 | 0.64 | MEN1 (0.44) | MEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250382297-A1 | INHIBITORS OF FGFR2 AND FGFR3 AND USES THEREOF | INSILICO MEDICINE IP LTD (HK) | 2025-12-18 | — | — | US | disclosed |
| EP-4547669-A1 | INHIBITORS OF FGFR2 AND FGFR3 AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2025-05-07 | — | — | EP | disclosed |
| CN-119451964-A | FGFR2 and FGFR3 inhibitors and uses thereof | 英矽智能科技知识产权有限公司 | 2025-02-14 | — | — | CN | disclosed |
| WO-2024002157-A1 | INHIBITORS OF FGFR2 AND FGFR3 AND USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2024-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250382297-A1 | INHIBITORS OF FGFR2 AND FGFR3 AND USES THEREOF | FGFR3, FGFR2, FGFR1 | MEN1 1922/4885MAPT 2467/4885KMT2A 2220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.